STAT
AUGUST 7, 2024
The nation’s largest health care company pressed thousands of its clinicians to use a thinly tested medical device to screen people for artery disease, dramatically boosting payments from the federal government for years even though many of the patients were not sick, a STAT investigation found. The result was a torrent of sometimes questionable diagnoses of peripheral artery disease.
Pharmacy Times
AUGUST 7, 2024
Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
AUGUST 7, 2024
As I hurried to an important meeting about my Ph.D. dissertation one day in 2015, I slipped and fell on Iowa’s formidable winter ice. I quickly jumped up to prevent anyone from seeing me on the ground and got into my car. The immediate, excruciating pain told me that something really bad had happened. As I drove to my meeting in tears, I called my sister.
Pharmacy Times
AUGUST 7, 2024
Two pediatric oncology pharmacists emphasize pharmacists personalize supportive care, educate patients and their caregivers, advocate for patients, and collaborate with other health care workers.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
AUGUST 7, 2024
Centene is exiting six states through its WellCare Medicare Advantage subsidiary next year, investment bank Stephens has revealed. | WellCare is leaving six states next year, impacting more than 37,000 Centene members across the country.
Pharmacy Times
AUGUST 7, 2024
Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 7, 2024
This breakthrough can be significant in the development for a vaccine and other preventative measures to protect individuals from leishmaniasis.
STAT
AUGUST 7, 2024
LONDON — Patients in England with a rare blood disorder will now be able to receive the world’s first CRISPR-based medicine, after drugmaker Vertex Pharmaceuticals and U.K. health officials struck a reimbursement deal for the pricey treatment. The National Institute for Health and Care Excellence, the U.K.’s cost-effectiveness watchdog, said early Thursday that it was recommending the treatment, called Casgevy, for certain patients with beta thalassemia, a condition that oth
Pharmacy Times
AUGUST 7, 2024
This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.
STAT
AUGUST 7, 2024
Purdue Pharma, the company best known for fueling the opioid crisis by misleadingly marketing the infamous painkiller OxyContin, received approval on Wednesday for a new auto-injector device used to reverse opioid overdoses. The announcement represents the latest in a string of recent approvals for products that use nalmefene, essentially a more powerful version of its better-known chemical cousin, naloxone.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmafile
AUGUST 7, 2024
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to treat neurodegenerative diseases. Sangamo is expected to receive $50m in near-term upfront license fees and milestone payments after granting Genentech exclusive licensing for its proprietary zinc finger repressors – that are directed to the tau […] The post Sangamo Therapeutics and Genentech team up to develop genomic medicines for
Pharmacy Times
AUGUST 7, 2024
The ADA Clinical Practice Recommendations added sleep assessment for precision medicine in type 2 diabetes, supporting the wealth of information surrounding the association.
Fierce Healthcare
AUGUST 7, 2024
As it seeks to boost its financial fortunes, CVS Health has "identified a multiyear opportunity" to generate as much as $2 billion in savings, CEO Karen Lynch told investors Wednesday. | As it seeks to boost its financial fortunes, CVS Health has "identified a multiyear opportunity" to generate as much as $2 billion in savings, CEO Karen Lynch told investors Wednesday.
Fierce Pharma
AUGUST 7, 2024
The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. | The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
AUGUST 7, 2024
Coming off a recent debt financing round, NeueHealth reported a net loss but small adjusted EBITDA profit during its second-quarter earnings results. | NeueHealth's second-quarter results were without significant surprises, though the company noted a moderate increase in membership.
pharmaphorum
AUGUST 7, 2024
Explore the innovative applications of mRNA technologies beyond COVID-19 vaccines. Learn about the potential and future developments in this groundbreaking field.
Drug Topics
AUGUST 7, 2024
In a recent conversation with Drug Topics on Over the Counter, Mark Garofoli discusses why men avoid seeking medical help for pain, as well as potential solutions.
STAT
AUGUST 7, 2024
The polarized debate over drug pricing has generated cartoonish, sometimes colorful caricatures of the biopharmaceutical industry and its leaders. Critics of the industry have portrayed pharmaceutical leaders as ruthless, rapacious leaders who gouge patients to gratify greedy shareholders. While one might expect industry trade organizations to defend their leaders, their responses have sometimes portrayed leaders as powerless proxies of their shareholders whose product portfolios and profits wou
Drug Topics
AUGUST 7, 2024
Make every month a celebration of wellbeing at the pharmacy by leveraging disease awareness initiatives.
STAT
AUGUST 7, 2024
LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming obesity medicine field sent Novo Nordisk’s shares down early Wednesday, as the company sought to project its ability to reach more patients by increasing the supplies of its medicines. Novo shares were down about 5% after the company lowered its operating profit guidance to 20% to 28%, down from the 22% to 30% it forecasted in its last earnings report.
Fierce Pharma
AUGUST 7, 2024
Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025.
STAT
AUGUST 7, 2024
CVS Health continued to pay out more than it expected for the medical claims of its Medicare Advantage enrollees in the second quarter, forcing the company to lower its estimates for this year’s profits for the second straight quarter. Those higher medical costs led CVS chief executive Karen Lynch to remove Brian Kane , the president of Aetna, the subsidiary that operates all health insurance plans.
Hospital Pharmacy Europe
AUGUST 7, 2024
Karl-Johan Lindner and Marie Halvarsson, from the pharmacy at Västerås Hospital in Sweden, describe a new approach to improve the categorisation of medication errors that uses the skills of hospital pharmacists to reclassify reported incidents based on a given medication process. Most hospitalised patients receive medications during their stay. However, errors related to administering these medicines can occur and they are frequent, avoidable sources of patient harm.
pharmaphorum
AUGUST 7, 2024
BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian but is reining back its ambitions for the business, for now
STAT
AUGUST 7, 2024
Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug Wegovy for a common type of heart failure, saying that waiting for more data on cardiovascular outcomes could bolster its case. Trials of Wegovy in the condition, heart failure with preserved ejection fraction (or HFpEF), have primarily looked at the drug’s effects on symptoms and physical function.
Fierce Pharma
AUGUST 7, 2024
Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? | Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? In the second quarter, Tepezza generated $479 million in sales for an increase of 8% year over year and 13% sequentially.
STAT
AUGUST 7, 2024
The Centers for Medicare and Medicaid Services has finalized its rule easing reimbursement for medical device makers. Called Transitional Coverage for Emerging Technologies, the program gives device makers with products deemed “breakthrough” technology by the Food and Drug Administration a quicker way to secure Medicare coverage. The agency first introduced the rule last June.
pharmaphorum
AUGUST 7, 2024
Weaker sales of obesity drug Wegovy cause a dip in Novo Nordisk's share price, but CEO says volume growth is strong and will accelerate in second half
STAT
AUGUST 7, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We recap another slew of earnings reported this morning and last night. Let’s get straight into it.
pharmaphorum
AUGUST 7, 2024
Explore how artificial intelligence and machine learning are revolutionising the medical devices sector. Learn about the innovative technologies and how companies are navigating evolving regulations in this rapidly advancing field.
STAT
AUGUST 7, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
pharmaphorum
AUGUST 7, 2024
A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with osteoarthritis in a phase 2 trial.Neurotrophin-3 (NT-3) inhibitor LEVI-04 hit all its primary and secondary objectives in the trial, which enrolled 510 patients with moderate-to-severe osteoarthritis of the knee, raising the hope it could become a non-addictive option for patients needing chronic pain relief.
Fierce Pharma
AUGUST 7, 2024
In a deal worth approximately $405 million, Danish drugmaker Pharmacosmos has agreed to acquire G1 Therapeutics and the latter company's flagship product Cosela. | The companies will team up to expand the reach of G1's Cosela, which is used to reduce bone marrow damage associated with certain chemotherapy regimens.
Pharmacy Times
AUGUST 7, 2024
Following a healthy, vitamin rich diet with less sugar was connected to a lower epigenetic age.
Expert insights. Personalized for you.
145 
Let's personalize your content